-
Kyung-Ah
Park,
F.
Ciardiello,
T.
Hida,
W.
Lim,
C.
Lin,
H.
Murakami,
M.
Nishio,
F.
Cantero,
V.
Cattan,
C.
Gabarroca,
E.
Gandossi,
L.
Paz-Ares
(2017)
1379TiPPhase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor
Annals of Oncology, 28
-
D.
Planchard,
E.
Smit,
H.
Groen,
J.
Mazières,
B.
Besse,
Å.
Helland,
V.
Giannone,
A.
D'Amelio,
Pingkuan
Zhang,
B.
Mookerjee,
B.
Johnson
(2016)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
The Lancet. Oncology, 18 10
-
Tzu-Hua
Chang,
Meng-Feng
Tsai,
K.
Su,
Shang-Gin
Wu,
Cheng‐Po
Huang,
Sung-Liang
Yu,
Yung-Luen
Yu,
C.
Lan,
Chih‐Hsin
Yang,
Shwu-Bin
Lin,
Chin-Pyng
Wu,
J.
Shih,
Pan‐Chyr
Yang
(2011)
Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
American journal of respiratory and critical care medicine, 183 8
-
K.
Ohashi,
L.
Sequist,
M.
Arcila,
T.
Morán,
J.
Chmielecki,
Ya-Lun
Lin,
Yumei
Pan,
Lu
Wang,
E.
Stanchina,
K.
Shien,
K.
Aoe,
S.
Toyooka,
K.
Kiura,
L.
Fernandez-Cuesta,
P.
Fidias,
J.
Yang,
V.
Miller,
Gregory
Riely,
M.
Kris,
J.
Engelman,
C.
Vnencak-Jones,
D.
Dias-Santagata,
M.
Ladanyi,
W.
Pao
(2012)
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
Proceedings of the National Academy of Sciences, 109
-
S.
Ou,
R.
Govindan,
K.
Eaton,
G.
Otterson,
M.
Gutierrez,
A.
Mita,
A.
Argiris,
N.
Brega,
T.
Usari,
Weiwei
Tan,
S.
Ho,
F.
Robert
(2017)
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
Journal of Thoracic Oncology, 12
-
L.
Sequist,
J.
Yang,
N.
Yamamoto,
K.
O'Byrne,
V.
Hirsh,
T.
Mok,
Sarayut
Geater,
S.
Orlov,
C.
Tsai,
M.
Boyer,
W.
Su,
J.
Bennouna,
T.
Kato,
V.
Gorbunova,
K.
Lee,
R.
Shah,
D.
Massey,
V.
Zazulina,
M.
Shahidi,
M.
Schuler
(2013)
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 27
-
Ji-Youn
Han,
Jin
Kim,
Suk
Lee,
N.
Yoo,
B.
Choi
(2011)
Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer.
Lung cancer, 74 2
-
Chih‐An
Lin,
Sung-Liang
Yu,
Hsuan-Yu
Chen,
Huei-Wen
Chen,
Shr-Uen
Lin,
Chia‐Ching
Chang,
Chong-Jen
Yu,
Pan‐Chyr
Yang,
Chao-Chi
Ho
(2019)
EGFR‐Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs
Journal of Thoracic Oncology, 14
-
Shengwu
Liu,
Shuai
Li,
J.
Hai,
Xiaoen
Wang,
Ting
Chen,
Max
Quinn,
P.
Gao,
Yanxi
Zhang,
H.
Ji,
D.
Cross,
Kwok-kin
Wong
(2018)
Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib
Clinical Cancer Research, 24
-
(2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
-
Vanessa
Jonsson,
C.
Blakely,
Luping
Lin,
S.
Asthana,
N.
Matni,
V.
Olivas,
E.
Pazarentzos,
M.
Gubens,
B.
Bastian,
B.
Taylor,
John
Doyle,
T.
Bivona
(2016)
Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
Scientific Reports, 7
-
Yongik
Lee,
Yian
Wang,
Michael
James,
Joseph
Jeong,
M.
You
(2016)
Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells
Molecular Carcinogenesis, 55
-
K.
Azuma,
T.
Hirashima,
N.
Yamamoto,
I.
Okamoto,
Toshiaki
Takahashi,
M.
Nishio,
T.
Hirata,
K.
Kubota,
K.
Kasahara,
T.
Hida,
H.
Yoshioka,
Kaoru
Nakanishi,
S.
Akinaga,
K.
Nishio,
T.
Mitsudomi,
K.
Nakagawa
(2016)
Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
ESMO Open, 1
-
M.
Chiba,
Y.
Togashi,
Eri
Bannno,
Yoshihisa
Kobayashi,
Yusuke
Nakamura,
H.
Hayashi,
M.
Terashima,
M.
Velasco,
K.
Sakai,
Y.
Fujita,
T.
Mitsudomi,
K.
Nishio
(2017)
Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
BMC Cancer, 17
-
Ji-Young
Song,
Choung-Soo
Kim,
Je-Hwan
Lee,
S.
Jang,
Sang-Wook
Lee,
J.
Hwang,
Chulsoo
Lim,
Gilnam
Lee,
Jeongbeob
Seo,
Suk
Cho,
Jene
Choi
(2013)
Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation
Investigational New Drugs, 31
-
K.
Suda,
K.
Tomizawa,
M.
Fujii,
H.
Murakami,
H.
Osada,
Y.
Maehara,
Y.
Yatabe,
Y.
Sekido,
T.
Mitsudomi
(2011)
Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib
Journal of Thoracic Oncology, 6
-
Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer
-
Phase II trial of cabozantinib plus erlotinib in patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with progressive disease on epidermal growth factor receptor tyrosine kinase inhibitor therapy: a California Cancer Consortium phase II trial (NCI 9303)
-
J.
Soria,
Yi-long
Wu,
K.
Nakagawa,
Sang-We
Kim,
Jin-Ji
Yang,
M.
Ahn,
Jie
Wang,
Jie
Yang,
You
Lu,
S.
Atagi,
S.
Ponce,
Dae-Ho
Lee,
Yunpeng
Liu,
K.
Yoh,
Jian-Ying
Zhou,
Xiaojin
Shi,
A.
Webster,
Haiyi
Jiang,
T.
Mok
(2015)
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
The Lancet. Oncology, 16 8
-
M.
Niederst,
L.
Sequist,
J.
Poirier,
C.
Mermel,
Elizabeth
Lockerman,
Angel
Garcia,
Ryohei
Katayama,
C.
Costa,
K.
Ross,
T.
Morán,
Emily
Howe,
L.
Fulton,
Hillary
Mulvey,
Lindsay
Bernardo,
Farhiya
Mohamoud,
N.
Miyoshi,
P.
VanderLaan,
D.
Costa,
P.
Jänne,
D.
Borger,
Sridhar
Ramaswamy,
T.
Shioda,
A.
Iafrate,
G.
Getz,
C.
Rudin,
M.
Mino‐Kenudson,
J.
Engelman
(2015)
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Nature Communications, 6
-
L.
Byers,
L.
Diao,
Jing
Wang,
P.
Saintigny,
L.
Girard,
M.
Peyton,
Li
Shen,
Youhong
Fan,
U.
Giri,
Praveen
Tumula,
M.
Nilsson,
J.
Gudikote,
H.
Tran,
R.
Cardnell,
D.
Bearss,
S.
Warner,
J.
Foulks,
S.
Kanner,
V.
Gandhi,
N.
Krett,
S.
Rosen,
Edward
Kim,
R.
Herbst,
G.
Blumenschein,
J.
Lee,
S.
Lippman,
K.
Ang,
G.
Mills,
W.
Hong,
J.
Weinstein,
I.
Wistuba,
K.
Coombes,
J.
Minna,
J.
Heymach
(2012)
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Clinical Cancer Research, 19
-
Kyung-A
Song,
M.
Niederst,
Timothy
Lochmann,
A.
Hata,
Hidenori
Kitai,
Jungoh
Ham,
K.
Floros,
M.
Hicks,
Haichuan
Hu,
Hillary
Mulvey,
Y.
Drier,
D.
Heisey,
Mark
Hughes,
Neha
Patel,
Elizabeth
Lockerman,
Angel
Garcia,
Shawn
Gillepsie,
Hannah
Archibald,
María
Gomez-Caraballo,
Tara
Nulton,
Brad
Windle,
Z.
Piotrowska,
S.
Sahingur,
Shirley
Taylor,
M.
Dozmorov,
L.
Sequist,
B.
Bernstein,
H.
Ebi,
J.
Engelman,
A.
Faber
(2017)
Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM
Clinical Cancer Research, 24
-
L.
Sequist,
B.
Waltman,
D.
Dias-Santagata,
S.
Digumarthy,
Alexa
Turke,
P.
Fidias,
K.
Bergethon,
A.
Shaw,
S.
Gettinger,
A.
Cosper,
S.
Akhavanfard,
R.
Heist,
J.
Temel,
J.
Christensen,
J.
Wain,
T.
Lynch,
Kathy
Vernovsky,
E.
Mark,
M.
Lanuti,
A.
Iafrate,
M.
Mino‐Kenudson,
J.
Engelman
(2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Science Translational Medicine, 3
-
E.
Jordan,
H.
Kim,
M.
Arcila,
D.
Barron,
D.
Chakravarty,
Jianjiong
Gao,
Matthew
Chang,
A.
Ni,
Ritika
Kundra,
P.
Jonsson,
G.
Jayakumaran,
S.
Gao,
Hannah
Johnsen,
Aphrothiti
Hanrahan,
A.
Zehir,
N.
Rekhtman,
M.
Ginsberg,
Bob
Li,
H.
Yu,
P.
Paik,
A.
Drilon,
M.
Hellmann,
D.
Reales,
R.
Benayed,
V.
Rusch,
M.
Kris,
J.
Chaft,
J.
Baselga,
B.
Taylor,
N.
Schultz,
C.
Rudin,
D.
Hyman,
M.
Berger,
D.
Solit,
M.
Ladanyi,
Gregory
Riely
(2017)
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
Cancer discovery, 7 6
-
Jeffrey
Thompson,
S.
Yee,
A.
Troxel,
Samantha
Savitch,
Ryan
Fan,
D.
Balli,
David
Lieberman,
J.
Morrissette,
T.
Evans,
J.
Bauml,
C.
Aggarwal,
J.
Kosteva,
E.
Alley,
C.
Ciunci,
R.
Cohen,
S.
Bagley,
Susan
Stonehouse-Lee,
V.
Sherry,
Elizabeth
Gilbert,
C.
Langer,
A.
Vachani,
E.
Carpenter
(2016)
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Clinical Cancer Research, 22
-
S.
Yano,
Wei
Wang,
Qi
Li,
Kunio
Matsumoto,
Haruko
Sakurama,
Takahiro
Nakamura,
H.
Ogino,
S.
Kakiuchi,
M.
Hanibuchi,
Y.
Nishioka,
H.
Uehara,
T.
Mitsudomi,
Y.
Yatabe,
Toshikazu
Nakamura,
S.
Sone
(2008)
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
Cancer research, 68 22
-
P.
Fan,
G.
Narzisi,
A.
Jayaprakash,
E.
Venturini,
N.
Robine,
Peter
Smibert,
S.
Germer,
H.
Yu,
E.
Jordan,
P.
Paik,
Y.
Janjigian,
J.
Chaft,
Lu
Wang,
A.
Jungbluth,
S.
Middha,
L.
Spraggon,
H.
Qiao,
C.
Lovly,
M.
Kris,
Gregory
Riely,
K.
Politi,
H.
Varmus,
M.
Ladanyi
(2018)
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
Proceedings of the National Academy of Sciences of the United States of America, 115
-
D.
Westover,
J.
Zugazagoitia,
B.
Cho,
C.
Lovly,
L.
Paz-Ares
(2018)
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
Annals of Oncology, 29
-
J.
Tung,
Po‐Lin
Lin,
Yao-Chen
Wang,
De-Wei
Wu,
Chi-yi
Chen,
Hue
Lee
(2017)
PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression
Oncotarget, 9
-
K.
Haratani,
H.
Hayashi,
Tae
Tanaka,
H.
Kaneda,
Y.
Togashi,
K.
Sakai,
Kentaro
Hayashi,
S.
Tomida,
Y.
Chiba,
K.
Yonesaka,
Yoshikane
Nonagase,
T.
Takahama,
J.
Tanizaki,
Kaoru
Tanaka,
T.
Yoshida,
K.
Tanimura,
M.
Takeda,
H.
Yoshioka,
Tadashi
Ishida,
T.
Mitsudomi,
K.
Nishio,
K.
Nakagawa
(2017)
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
Annals of Oncology, 28
-
L.
Ferrer,
M.
Levra,
M.
Brevet,
M.
Antoine,
J.
Mazières,
G.
Rossi,
R.
Chiari,
V.
Westeel,
M.
Poudenx,
J.
Letreut,
R.
Gervais,
G.
Osman,
N.
Girard,
A.
Toffart,
S.
Novello,
D.
Moro-Sibilot
(2019)
A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics
Journal of Thoracic Oncology, 14
-
(2007)
Bim mediates EGFR tyrosine kinase inhibitor induced apoptosis in non-small cell lung cancers and is linked to the resistance conferred by secondary EGFR mutations, T790M and the novel L747S
-
K.
Azuma,
K.
Ota,
A.
Kawahara,
S.
Hattori,
E.
Iwama,
T.
Harada,
Koichiro
Matsumoto,
K.
Takayama,
S.
Takamori,
M.
Kage,
T.
Hoshino,
Y.
Nakanishi,
I.
Okamoto
(2014)
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 25 10
-
A.
Schrock,
V.
Zhu,
W.
Hsieh,
R.
Madison,
B.
Creelan,
J.
Silberberg,
D.
Costin,
A.
Bharne,
Ioana
Bonta,
Thangavijayan
Bosemani,
P.
Nikolinakos,
J.
Ross,
V.
Miller,
Siraj
Ali,
S.
Klempner,
S.
Ou
(2018)
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
Journal of Thoracic Oncology, 13
-
F.
Cappuzzo,
P.
Jänne,
M.
Skokan,
G.
Finocchiaro,
E.
Rossi,
C.
Ligorio,
P.
Zucali,
L.
Terracciano,
L.
Toschi,
M.
Roncalli,
A.
Destro,
M.
Incarbone,
M.
Alloisio,
A.
Santoro,
M.
Varella-Garcia
(2009)
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology, 20 2
-
H.
Yu,
K.
Suzawa,
E.
Jordan,
A.
Zehir,
A.
Ni,
R.
Kim,
M.
Kris,
M.
Hellmann,
Bob
Li,
R.
Somwar,
D.
Solit,
M.
Berger,
M.
Arcila,
Gregory
Riely,
M.
Ladanyi
(2018)
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
Clinical Cancer Research, 24
-
V.
Papadimitrakopoulou
(2012)
Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 7 8
-
T.
Mitsudomi,
S.
Morita,
Y.
Yatabe,
S.
Negoro,
I.
Okamoto,
J.
Tsurutani,
T.
Seto,
M.
Satouchi,
H.
Tada,
T.
Hirashima,
K.
Asami,
N.
Katakami,
M.
Takada,
H.
Yoshioka,
K.
Shibata,
S.
Kudoh,
E.
Shimizu,
H.
Saito,
S.
Toyooka,
K.
Nakagawa,
M.
Fukuoka
(2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
The Lancet. Oncology, 11 2
-
S.
Peters,
R.
Stahel,
L.
Bubendorf,
P.
Bonomi,
A.
Villegas,
D.
Kowalski,
C.
Baik,
D.
Isla,
J.
Carpeño,
P.
Garrido,
A.
Rittmeyer,
M.
Tiseo,
Christoph
Meyenberg,
S.
Haas,
L.
Lam,
Michael
Lu,
T.
Stinchcombe
(2018)
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Clinical Cancer Research, 25
-
Yi-long
Wu,
Li
Zhang,
Dong-Wan
Kim,
Xiaoqing
Liu,
Dae-Ho
Lee,
J.
Yang,
M.
Ahn,
J.
Vansteenkiste,
W.
Su,
E.
Felip,
V.
Chia,
S.
Glaser,
P.
Pultar,
Sylvia
Zhao,
B.
Peng,
M.
Akimov,
D.
Tan
(2018)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 31
-
P.
Lara,
J.
Longmate,
P.
Mack,
K.
Kelly,
M.
Socinski,
R.
Salgia,
B.
Gitlitz,
Tianhong
Li,
M.
Koczywas,
K.
Reckamp,
D.
Gandara
(2015)
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib
Clinical Cancer Research, 21
-
H.
Yu,
M.
Arcila,
N.
Rekhtman,
C.
Sima,
M.
Zakowski,
W.
Pao,
M.
Kris,
V.
Miller,
M.
Ladanyi,
Gregory
Riely
(2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Clinical Cancer Research, 19
-
T.
Mok,
Sang-We
Kim,
Yi-long
Wu,
K.
Nakagawa,
Jin-Ji
Yang,
M.
Ahn,
Jie
Wang,
Jie
Yang,
You
Lu,
S.
Atagi,
S.
Ponce,
Xiaojin
Shi,
Y.
Rukazenkov,
V.
Haddad,
K.
Thress,
J.
Soria
(2017)
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 36
-
R.
Rosell,
E.
Carcereny,
R.
Gervais,
A.
Vergnenègre,
B.
Massutí,
E.
Felip,
R.
Palmero,
R.
García-Gómez,
C.
Pallarés,
J.
Sánchez,
R.
Porta,
M.
Cobo,
P.
Garrido,
F.
Longo,
T.
Morán,
A.
Insa,
F.
Marinis,
R.
Corre,
I.
Bover,
A.
Illiano,
É.
Dansin,
J.
Castro,
M.
Milella,
N.
Reguart,
G.
Altavilla,
U.
Jiménez,
M.
Provencio,
M.
Moreno,
J.
Terrasa,
J.
Muñoz-Langa,
J.
Valdivia,
D.
Isla,
M.
Dómine,
O.
Molinier,
J.
Mazières,
N.
Baize,
R.
García-Campelo,
G.
Robinet,
D.
Rodríguez-Abreu,
G.
López-Vivanco,
V.
Gebbia,
Lioba
Ferrera-Delgado,
P.
Bombaron,
R.
Bernabé,
A.
Bearz,
Á.
Artal,
E.
Cortesi,
C.
Rolfo,
M.
Sánchez-Ronco,
A.
Drozdowskyj,
C.
Queralt,
I.
Aguirre,
J.
Ramírez,
J.
Sánchez,
M.
Molina,
M.
Taron,
L.
Paz-Ares
(2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
The Lancet. Oncology, 13 3
-
M.
Balak,
Y.
Gong,
Gregory
Riely,
R.
Somwar,
Allan
Li,
M.
Zakowski,
Anne
Chiang,
Guangli
Yang,
O.
Ouerfelli,
M.
Kris,
M.
Ladanyi,
V.
Miller,
W.
Pao
(2006)
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
Clinical Cancer Research, 12
-
Sabrina
Baltschukat,
B.
Engstler,
A.
Huang,
Huai-Xiang
Hao,
Angela
Tam,
H.
Wang,
Jinsheng
Liang,
Matthew
DiMare,
Hyo-eun
Bhang,
Youzhen
Wang,
P.
Furet,
W.
Sellers,
F.
Hofmann,
J.
Schoepfer,
R.
Tiedt
(2019)
Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
Clinical Cancer Research, 25
-
J.
Gainor,
M.
Niederst,
J.
Lennerz,
I.
Dagogo-Jack,
S.
Stevens,
A.
Shaw,
L.
Sequist,
J.
Engelman
(2016)
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 11 7
-
E.
Krall,
Belinda
Wang,
D.
Muñoz,
N.
Ilić,
Srivatsan
Raghavan,
M.
Niederst,
Kristine
Yu,
D.
Ruddy,
A.
Aguirre,
Jong
Kim,
A.
Redig,
J.
Gainor,
J.
Williams,
J.
Asara,
John
Doench,
P.
Janne,
A.
Shaw,
Robert
Iii,
J.
Engelman,
F.
Stegmeier,
M.
Schlabach,
W.
Hahn
(2017)
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
eLife, 6
-
Caicun
Zhou,
Yi-long
Wu,
Gongyan
Chen,
Jifeng
Feng,
Xiao‐qing
Liu,
Chang-li
Wang,
Shucai
Zhang,
Jie
Wang,
Songwen
Zhou,
S.
Ren,
Shun
Lu,
Li
Zhang,
Chengping
Hu,
Chunhong
Hu,
Yi
Luo,
Lei
Chen,
M.
Ye,
Jianan
Huang,
X.
Zhi,
Yiping
Zhang,
Q.
Xiu,
Jun
Ma,
C.
You
(2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
The Lancet. Oncology, 12 8
-
Sendurai
Mani,
Wenjun
Guo,
Mai-Jing
Liao,
E.
Eaton,
Ayyakkannu
Ayyanan,
A.
Zhou,
M.
Brooks,
Ferenc
Reinhard,
C.
Zhang,
M.
Shipitsin,
Lauren
Campbell,
K.
Polyak,
C.
Brisken,
Jing
Yang,
R.
Weinberg
(2008)
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Cell, 133
-
S.
Nanjo,
Tadaaki
Yamada,
H.
Nishihara,
S.
Takeuchi,
Takako
Sano,
T.
Nakagawa,
Daisuke
Ishikawa,
Lu
Zhao,
H.
Ebi,
K.
Yasumoto,
Kunio
Matsumoto,
S.
Yano
(2013)
Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
PLoS ONE, 8
-
K.
Suzawa,
M.
Offin,
A.
Schoenfeld,
A.
Plodkowski,
I.
Odintsov,
D.
Lu,
W.
Lockwood,
M.
Arcila,
C.
Rudin,
A.
Drilon,
H.
Yu,
Gregory
Riely,
R.
Somwar,
M.
Ladanyi
(2019)
Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer
JCO Precision Oncology, 3
-
J.
Engelman,
K.
Zejnullahu,
T.
Mitsudomi,
Youngchul
Song,
Courtney
Hyland,
Joon-Oh
Park,
N.
Lindeman,
Christopher-Michael
Gale,
Xiaojun
Zhao,
J.
Christensen,
T.
Kosaka,
A.
Holmes,
A.
Rogers,
F.
Cappuzzo,
T.
Mok,
Charles
Lee,
B.
Johnson,
L.
Cantley,
P.
Jänne
(2007)
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Science, 316
-
J.
Bean,
C.
Brennan,
J.
Shih,
Gregory
Riely,
A.
Viale,
Lu
Wang,
D.
Chitale,
N.
Motoi,
J.
Szőke,
S.
Broderick,
M.
Balak,
Wen‐Cheng
Chang,
Chong-Jen
Yu,
Adi
Gazdar,
H.
Pass,
V.
Rusch,
W.
Gerald,
Shiu-Feng
Huang,
Pan‐Chyr
Yang,
V.
Miller,
M.
Ladanyi,
Chih‐Hsin
Yang,
W.
Pao
(2007)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Proceedings of the National Academy of Sciences, 104
-
J.
Yang,
V.
Hirsh,
M.
Schuler,
N.
Yamamoto,
K.
O'Byrne,
T.
Mok,
V.
Zazulina,
M.
Shahidi,
J.
Lungershausen,
D.
Massey,
M.
Palmer,
L.
Sequist
(2013)
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 27
-
J.
Rho,
Yun-Jung
Choi,
Seon
Kim,
Tae
Kim,
E.
Choi,
Seon-Joo
Yoon,
B.
Park,
Eunhye
Park,
J.
Bae,
Chang-Min
Choi,
Jae
Lee
(2014)
MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Cancer research, 74 1
-
Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR
-
Jinnan
Yue,
D.
Lv,
Caiyun
Wang,
Ling
Li,
Qingnan
Zhao,
Hongzhuan
Chen,
Lu
Xu
(2018)
Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3
Oncogene, 37
-
J.
Yang,
M.
Ahn,
Dong-Wan
Kim,
S.
Ramalingam,
L.
Sequist,
W.
Su,
Sang-We
Kim,
Joo‐Hang
Kim,
D.
Planchard,
E.
Felip,
F.
Blackhall,
D.
Haggstrom,
K.
Yoh,
S.
Novello,
K.
Gold,
T.
Hirashima,
Chia‐Chi
Lin,
H.
Mann,
M.
Cantarini,
S.
Ghiorghiu,
P.
Jänne
(2017)
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 12
-
Shang-Gin
Wu,
Yi-nan
Liu,
Meng-Feng
Tsai,
Yih-Leong
Chang,
Chong-Jen
Yu,
Pan‐Chyr
Yang,
J.
Yang,
Yueh-Feng
Wen,
J.
Shih
(2016)
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
Oncotarget, 7
-
S.
Gettinger,
M.
Hellmann,
L.
Chow,
H.
Borghaei,
S.
Antonia,
J.
Brahmer,
J.
Goldman,
D.
Gerber,
R.
Juergens,
F.
Shepherd,
S.
Laurie,
Tina
Young,
Xuemei
Li,
W.
Geese,
N.
Rizvi
(2018)
Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC
Journal of Thoracic Oncology, 13
-
K.
Nosaki,
M.
Satouchi,
T.
Kurata,
T.
Yoshida,
I.
Okamoto,
N.
Katakami,
F.
Imamura,
Kaoru
Tanaka,
Y.
Yamane,
N.
Yamamoto,
T.
Kato,
K.
Kiura,
H.
Saka,
H.
Yoshioka,
Kana
Watanabe,
K.
Mizuno,
T.
Seto
(2016)
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study.
Lung cancer, 101
-
S.
Ou,
L.
Horn,
M.
Cruz,
D.
Vafai,
C.
Lovly,
Allison
Spradlin,
M.
Williamson,
I.
Dagogo-Jack,
Adrienne
Johnson,
V.
Miller,
S.
Gadgeel,
Siraj
Ali,
A.
Schrock
(2017)
Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients
Lung cancer (Amsterdam, Netherlands), 111
-
K.
Yonesaka,
K.
Hirotani,
H.
Kawakami,
M.
Takeda,
H.
Kaneda,
K.
Sakai,
I.
Okamoto,
K.
Nishio,
P.
Jänne,
P.
Jänne,
K.
Nakagawa
(2016)
Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib
Oncogene, 35
-
M.
Johnson,
H.
Yu,
E.
Hart,
B.
Weitner,
A.
Rademaker,
J.
Patel,
M.
Kris,
Gregory
Riely
(2015)
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 15
-
J.
Bean,
Gregory
Riely,
M.
Balak,
J.
Marks,
M.
Ladanyi,
V.
Miller,
W.
Pao
(2008)
Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma
Clinical Cancer Research, 14
-
Z.
Yao,
Silvia
Fenoglio,
Dingcheng
Gao,
M.
Camiolo,
B.
Stiles,
Trine
Lindsted,
M.
Schlederer,
C.
Johns,
N.
Altorki,
V.
Mittal,
L.
Kenner,
Raffaella
Sordella
(2010)
TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
Proceedings of the National Academy of Sciences, 107
-
Bin-Chi
Liao,
Ya-Ying
Bai,
Jih-hsiang
Lee,
Chia‐Chi
Lin,
Shu-Yung
Lin,
Yee-Fan
Lee,
Chao-Chi
Ho,
J.
Shih,
Yeun-Chung
Chang,
Chong-Jen
Yu,
J.
Yang,
Pan‐Chyr
Yang
(2017)
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors.
Journal of the Formosan Medical Association = Taiwan yi zhi, 117 4
-
N.
Leighl,
R.
Page,
V.
Raymond,
D.
Daniel,
S.
Divers,
K.
Reckamp,
M.
Villalona-Calero,
D.
Dix,
J.
Odegaard,
R.
Lanman,
V.
Papadimitrakopoulou
(2019)
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
Clinical Cancer Research, 25
-
Hiroki
Sato,
K.
Shien,
S.
Tomida,
Kazuhiro
Okayasu,
K.
Suzawa,
Shinsuke
Hashida,
Hidejiro
Torigoe,
Mototsugu
Watanabe,
H.
Yamamoto,
J.
Soh,
Hiroaki
Asano,
K.
Tsukuda,
S.
Miyoshi,
S.
Toyooka
(2017)
Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features
Scientific Reports, 7
-
T.
Yamaoka,
T.
Ohmori,
M.
Ohba,
S.
Arata,
Y.
Murata,
S.
Kusumoto,
Koichi
Ando,
H.
Ishida,
T.
Ohnishi,
Y.
Sasaki
(2017)
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation
Molecular Cancer Research, 15
-
G.
Masters,
S.
Temin,
C.
Azzoli,
G.
Giaccone,
Sherman
Baker,
J.
Brahmer,
P.
Ellis,
A.
Gajra,
Nancy
Rackear,
J.
Schiller,
Thomas
Smith,
John
Strawn,
D.
Trent,
David
Johnson
(2015)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 30
-
S.
Yamazaki,
Youichi
Higuchi,
Masayuki
Ishibashi,
H.
Hashimoto,
M.
Yasunaga,
Y.
Matsumura,
K.
Tsuchihara,
M.
Tsuboi,
K.
Goto,
A.
Ochiai,
G.
Ishii
(2018)
Collagen type I induces EGFR‐TKI resistance in EGFR‐mutated cancer cells by mTOR activation through Akt‐independent pathway
Cancer Science, 109
-
Y.
Janjigian,
E.
Smit,
H.
Groen,
L.
Horn,
S.
Gettinger,
D.
Camidge,
Gregory
Riely,
Bushi
Wang,
Yali
Fu,
V.
Chand,
V.
Miller,
W.
Pao
(2014)
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
Cancer discovery, 4 9
-
(2019)
Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: results from the phase Ib TATTON study
-
D.
Camidge,
T.
Morán,
I.
Demedts,
H.
Grosch,
J.
Mercurio,
K.
Mileham,
J.
Molina,
Ó.
Vidal,
G.
Bepler,
J.
Goldman,
C.
Lewanski,
Keunchil
Park,
J.
Wallin,
S.
Wijayawardana,
Xuejing
Wang,
V.
Wacheck,
E.
Smit
(2016)
A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.
Journal of Clinical Oncology, 34
-
T.
Mok,
Yi-long
Wu,
M.
Ahn,
M.
Garassino,
H.
Kim,
S.
Ramalingam,
F.
Shepherd,
Yong
He,
H.
Akamatsu,
W.
Theelen,
C.
Lee,
M.
Sebastian,
A.
Templeton,
H.
Mann,
M.
Marotti,
S.
Ghiorghiu,
V.
Papadimitrakopoulou
(2017)
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
The New England Journal of Medicine, 376
-
D.
Camidge,
F.
Barlesi,
J.
Goldman,
D.
Morgensztern,
R.
Heist,
E.
Vokes,
A.
Spira,
E.
Angevin,
W.
Su,
D.
Hong,
J.
Strickler,
M.
Motwani,
Zhaowen
Sun,
A.
Parikh,
E.
Noon,
J.
Wu,
K.
Kelly
(2019)
Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.
Journal of Clinical Oncology
-
Ho-June
Lee,
G.
Zhuang,
Yi
Cao,
P.
Du,
Hyo-Jin
Kim,
J.
Settleman
(2014)
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
Cancer cell, 26 2
-
Yi-long
Wu,
Ying
Cheng,
Xiang-dong
Zhou,
K.
Lee,
K.
Nakagawa,
S.
Niho,
F.
Tsuji,
R.
Linke,
R.
Rosell,
J.
Corral,
M.
Migliorino,
A.
Płużański,
E.
Sbar,
Tao
Wang,
Jane
White,
S.
Nadanaciva,
R.
Sandin,
T.
Mok
(2017)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
The Lancet. Oncology, 18 11
-
S.
Jenkins,
J.
Yang,
S.
Ramalingam,
K.
Yu,
Sabina
Patel,
S.
Weston,
R.
Hodge,
M.
Cantarini,
P.
Jänne,
T.
Mitsudomi,
G.
Goss
(2017)
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer
Journal of Thoracic Oncology, 12
-
S.
Klempner,
L.
Bazhenova,
F.
Braiteh,
P.
Nikolinakos,
Kyle
Gowen,
C.
Cervantes,
J.
Chmielecki,
J.
Greenbowe,
J.
Ross,
P.
Stephens,
V.
Miller,
Siraj
Ali,
S.
Ou
(2015)
Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Lung cancer, 89 3
-
A.
Hata,
N.
Katakami,
S.
Nanjo,
C.
Okuda,
R.
Kaji,
K.
Masago,
S.
Fujita,
H.
Yoshida,
Kota
Zama,
Y.
Imai,
Yukio
Hirata
(2017)
Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
Lung cancer, 111
-
N.
Marcoux,
S.
Gettinger,
G.
O’Kane,
K.
Arbour,
J.
Neal,
H.
Husain,
T.
Evans,
J.
Brahmer,
A.
Muzikansky,
P.
Bonomi,
S.
Prete,
A.
Wurtz,
A.
Farago,
D.
Dias-Santagata,
M.
Mino‐Kenudson,
K.
Reckamp,
H.
Yu,
H.
Wakelee,
F.
Shepherd,
Z.
Piotrowska,
L.
Sequist
(2019)
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37 4
-
Huiming
Pan,
T.
Jiang,
Ningning
Cheng,
Qi
Wang,
S.
Ren,
Xue-Fei
Li,
Chao
Zhao,
Limin
Zhang,
W.
Cai,
Caicun
Zhou
(2016)
Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer
Oncotarget, 7
-
D.
Planchard,
S.
Popat,
K.
Kerr,
S.
Novello,
E.
Smit,
C.
Faivre-Finn,
T.
Mok,
M.
Reck,
P.
Schil,
M.
Hellmann,
S.
Peters
(2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 29 Supplement_4
-
M.
Maemondo,
Inoue
(2010)
F1000 highlights
Asia‐Pacific Journal of Clinical Oncology, 6
-
Alexa
Turke,
K.
Zejnullahu,
Yi-long
Wu,
Youngchul
Song,
D.
Dias-Santagata,
E.
Lifshits,
L.
Toschi,
Andrew
Rogers,
T.
Mok,
L.
Sequist,
N.
Lindeman,
C.
Murphy,
S.
Akhavanfard,
B.
Yeap,
Yun
Xiao,
Yun
Xiao,
M.
Capelletti,
A.
Iafrate,
Charles
Lee,
J.
Christensen,
J.
Engelman,
P.
Jänne
(2010)
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
Cancer cell, 17 1
-
M.
Socinski,
R.
Jotte,
F.
Cappuzzo,
F.
Orlandi,
D.
Stroyakovskiy,
N.
Nogami,
D.
Rodríguez-Abreu,
D.
Moro-Sibilot,
C.
Thomas,
F.
Barlesi,
G.
Finley,
C.
Kelsch,
Anthony
Lee,
S.
Coleman,
Y.
Deng,
Yijing
Shen,
M.
Kowanetz,
A.
López-Chávez,
A.
Sandler,
M.
Reck
(2018)
Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC
The New England Journal of Medicine, 378
-
J.
Yang,
F.
Shepherd,
Dong-Wan
Kim,
Gyeong-Won
Lee,
J.
Lee,
G.
Chang,
S.
Lee,
Yu-Feng
Wei,
Yun-Gyoo
Lee,
G.
Laus,
B.
Collins,
F.
Pisetzky,
L.
Horn
(2019)
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
Journal of Thoracic Oncology, 14
-
J.
Lee,
J.
Lee,
Sehui
Kim,
Soyeon
Kim,
J.
Youk,
Seongyeol
Park,
Yohan
An,
B.
Keam,
Dong-Wan
Kim,
D.
Heo,
Y.
Kim,
Jin-Soo
Kim,
Se
Kim,
J.
Lee,
Se-Hoon
Lee,
Keunchil
Park,
J.
Ku,
Y.
Jeon,
D.
Chung,
P.
Park,
J.
Kim,
T.
Kim,
Y.
Ju
(2017)
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 26
-
M.
Reck,
T.
Mok,
M.
Nishio,
R.
Jotte,
F.
Cappuzzo,
F.
Orlandi,
D.
Stroyakovskiy,
N.
Nogami,
D.
Rodríguez-Abreu,
D.
Moro-Sibilot,
C.
Thomas,
F.
Barlesi,
G.
Finley,
Anthony
Lee,
S.
Coleman,
Y.
Deng,
M.
Kowanetz,
G.
Shankar,
W.
Lin,
M.
Socinski
(2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
The Lancet. Respiratory medicine, 7 5
-
K.
Takezawa,
V.
Pirazzoli,
M.
Arcila,
C.
Nebhan,
Xiaoling
Song,
E.
Stanchina,
K.
Ohashi,
Y.
Janjigian,
P.
Spitzler,
M.
Melnick,
Gregory
Riely,
M.
Kris,
V.
Miller,
M.
Ladanyi,
K.
Politi,
W.
Pao
(2012)
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Cancer discovery, 2 10
-
N.
Chen,
W.
Fang,
J.
Zhan,
Shaodong
Hong,
Yanna
Tang,
Shiyang
Kang,
Yaxiong
Zhang,
Xiaobo
He,
Ting
Zhou,
T.
Qin,
Yan
Huang,
Xianping
Yi,
Li
Zhang
(2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Journal of Thoracic Oncology, 10
-
Yuji
Otsuki,
H.
Saya,
Y.
Arima
(2018)
Prospects for new lung cancer treatments that target EMT signaling
Developmental Dynamics, 247
-
P.
Jänne,
G.
Oxnard,
K.
Thress,
R.
Alden,
R.
Lawrance
(2016)
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 28
-
S.
Gao,
Q.
Chang,
Ninghui
Mao,
L.
Daly,
Robert
Vogel,
T.
Chan,
S.
Liu,
E.
Bournazou,
Erez
Schori,
Haiying
Zhang,
M.
Brewer,
W.
Pao,
L.
Morris,
M.
Ladanyi,
M.
Arcila,
K.
Manova-Todorova,
E.
Stanchina,
L.
Norton,
R.
Levine,
G.
Altan-Bonnet,
D.
Solit,
M.
Zinda,
D.
Huszar,
D.
Lyden,
J.
Bromberg
(2016)
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
Science Signaling, 9
-
J.
Bromberg
(2002)
Stat proteins and oncogenesis.
The Journal of clinical investigation, 109 9
-
P.
Jänne,
H.
Yu,
M.
Johnson,
C.
Steuer,
M.
Vigliotti,
C.
Iacobucci,
Shuquan
Chen,
Channing
Yu,
D.
Sellami
(2019)
Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.
Journal of Clinical Oncology
-
GEOMETRY duo-1: a phase (Ph) Ib/II, multicenter trial of oral cMET inhibitor capmatinib (INC280) ± erlotinib vs platinum + pemetrexed in adult patients (pts) with epidermal growth factor receptor (EGFR)-mutated, cMET-amplified, locally advanced/metastatic non-small cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (TKI) therapy
-
F.
Passiglia,
S.
Rizzo,
M.
Maio,
A.
Galvano,
G.
Badalamenti,
A.
Listì,
L.
Gulotta,
M.
Castiglia,
F.
Fulfaro,
V.
Bazan,
A.
Russo
(2018)
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
Scientific Reports, 8
-
D.
Tan,
K.
Lim,
W.
Tai,
A.
Ahmad,
S.
Pan,
Q.
Ng,
M.
Ang,
A.
Gogna,
Y.
Ng,
B.
Tan,
H.
Lee,
S.
Krisna,
D.
Lau,
Liz
Zhong,
G.
Iyer,
B.
Chowbay,
A.
Lim,
A.
Takano,
W.
Lim,
E.
Tan
(2013)
A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib (gef) in EGFR TKI-resistant NSCLC.
Journal of Clinical Oncology, 31
-
Yaqiong
Tian,
Zengli
Zhang,
L.
Miao,
Zhimin
Yang,
Jie
Yang,
Yinhua
Wang,
Danwen
Qian,
H.
Cai,
Yongsheng
Wang
(2016)
Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells
Oncology Research, 24
-
M.
Guix,
A.
Faber,
S.
Wang,
M.
Olivares,
Youngchul
Song,
S.
Qu,
C.
Rinehart,
B.
Seidel,
D.
Yee,
C.
Arteaga,
J.
Engelman
(2008)
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
The Journal of clinical investigation, 118 7
-
S.
Yano,
Tadaaki
Yamada,
S.
Takeuchi,
Keisei
Tachibana,
Y.
Minami,
Y.
Yatabe,
T.
Mitsudomi,
Hidenori
Tanaka,
Tatsuo
Kimura,
S.
Kudoh,
H.
Nokihara,
Y.
Ohe,
J.
Yokota,
H.
Uramoto,
K.
Yasumoto,
K.
Kiura,
M.
Higashiyama,
M.
Oda,
H.
Saito,
J.
Yoshida,
Kazuya
Kondoh,
M.
Noguchi
(2011)
Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
-
Ming-Hung
Huang,
Jih-hsiang
Lee,
Ya-ju
Chang,
Hsin-Hui
Tsai,
Yu-Lin
Lin,
A.
Lin,
Jie
Yang
(2013)
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib
Molecular Oncology, 7
-
Zhenfeng
Zhang,
Jae
Lee,
Luping
Lin,
V.
Olivas,
Valerie
Au,
T.
LaFramboise,
Mohamed
Abdel-Rahman,
Xiaoqi
Wang,
A.
Levine,
J.
Rho,
Yun-Jung
Choi,
Chang-Min
Choi,
Sang-We
Kim,
S.
Jang,
Y.
Park,
W.
Kim,
Dae-Ho
Lee,
Jung-Shin
Lee,
V.
Miller,
M.
Arcila,
M.
Ladanyi,
P.
Moonsamy,
C.
Sawyers,
T.
Boggon,
P.
Ma,
C.
Costa,
M.
Taron,
R.
Rosell,
B.
Halmos,
T.
Bivona
(2012)
Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer
Nature genetics, 44
-
H.
Yu,
L.
Pérez,
Q.
Chang,
S.
Gao,
M.
Kris,
Gregory
Riely,
J.
Bromberg
(2017)
A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR‐Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib
Journal of Thoracic Oncology, 12
-
Chien-Hui
Weng,
Li-yu
Chen,
Yu‐Chin
Lin,
J.
Shih,
Yuntao
Lin,
Ruo-Yu
Tseng,
A.
Chiu,
Yu-Hsuan
Yeh,
Chi
Liu,
Yi-Ting
Lin,
Jim-Min
Fang,
Ching‐Chow
Chen
(2018)
Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI
Oncogene, 38
-
Lei
Wang,
Haichuan
Hu,
Yunjian
Pan,
Rui
Wang,
Yuan
Li,
L.
Shen,
Yongfu
Yu,
Hang
Li,
D.
Cai,
Yihua
Sun,
Haiquan
Chen
(2014)
PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
PLoS ONE, 9
-
G.
Goss,
C.
Tsai,
F.
Shepherd,
L.
Bazhenova,
J.
Lee,
G.
Chang,
L.
Crinò,
M.
Satouchi,
Q.
Chu,
T.
Hida,
Ji-Youn
Han,
Ó.
Juan,
F.
Dunphy,
M.
Nishio,
Jin-Hyoung
Kang,
M.
Majem,
H.
Mann,
M.
Cantarini,
S.
Ghiorghiu,
T.
Mitsudomi
(2016)
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
The Lancet. Oncology, 17 12
-
T.
John,
H.
Akamatsu,
A.
Delmonte,
W.
Su,
J.
Lee,
G.
Chang,
Xiangning
Huang,
S.
Jenkins,
Yi-long
Wu
(2018)
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
Lung cancer, 126
-
A.
Sacher,
C.
Paweletz,
S.
Dahlberg,
R.
Alden,
Allison
O'Connell,
N.
Feeney,
Stacy
Mach,
P.
Jänne,
G.
Oxnard
(2016)
Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
JAMA oncology, 2 8
-
Zachary
Yochum,
Jessica
Cades,
Hailun
Wang,
S.
Chatterjee,
B.
Simons,
J.
O'brien,
S.
Khetarpal,
Ghali
Lemtiri-Chlieh,
Kayla
Myers,
E.
Huang,
C.
Rudin,
P.
Tran,
T.
Burns
(2018)
Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
Oncogene, 38
-
Katsuhiro
Yoshimura,
N.
Inui,
M.
Karayama,
Y.
Inoue,
N.
Enomoto,
T.
Fujisawa,
Y.
Nakamura,
K.
Takeuchi,
H.
Sugimura,
T.
Suda
(2017)
Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
Respiratory Medicine Case Reports, 20
-
Y.
Wu,
J.
Zhou,
S.
Lu,
Y.
Zhang,
J.
Zhao,
H.
Pan,
Y-M.
Chen,
C.
Chian,
R.
Bruns,
A.
Johne,
J.
Scheele,
Y.
Cheng
(2018)
Tepotinib + gefitinib (TEP+GEF) in MET+/epidermal growth factor receptor (EGFR)-mutant non-small lung cancer (NSCLC): Phase II data.
Annals of oncology : official journal of the European Society for Medical Oncology, 29 Suppl 9
-
G.
Masters,
David
Johnson,
S.
Temin
(2016)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Journal of oncology practice / American Society of Clinical Oncology, 12 1
-
J.
Vansteenkiste,
J.
Canon,
F.
Braud,
F.
Grossi,
T.
Pas,
J.
Gray,
W.
Su,
E.
Felip,
H.
Yoshioka,
C.
Gridelli,
G.
Dy,
S.
Thongprasert,
M.
Reck,
P.
Aimone,
G.
Vidam,
P.
Roussou,
Ying
Wang,
E.
Tomaso,
J.
Soria
(2015)
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study
Journal of Thoracic Oncology, 10
-
J.
Yang,
S.
Gadgeel,
L.
Sequist,
Chien-Liang
Wu,
V.
Papadimitrakopoulou,
W.
Su,
J.
Fiore,
S.
Saraf,
H.
Raftopoulos,
A.
Patnaik
(2019)
Pembrolizumab in Combination With Erlotinib or Gefitinib as First‐Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
Journal of Thoracic Oncology, 14
-
Matthew
Lara,
W.
Holland,
Danielle
Chinn,
Rebekah
Burich,
P.
Lara,
D.
Gandara,
K.
Kelly,
P.
Mack
(2017)
Preclinical Evaluation of MET Inhibitor INC‐280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small‐Cell Lung Cancer
Clinical Lung Cancer, 18
-
Sidong
Huang,
M.
Hölzel,
T.
Knijnenburg,
A.
Schlicker,
P.
Roepman,
U.
McDermott,
M.
Garnett,
Wipawadee
Grernrum,
Chong
Sun,
A.
Prahallad,
F.
Groenendijk,
L.
Mittempergher,
Wouter
Nijkamp,
J.
Neefjes,
R.
Salazar,
P.
Dijke,
H.
Uramoto,
F.
Tanaka,
R.
Beijersbergen,
L.
Wessels,
R.
Bernards
(2012)
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Cell, 151
-
Takahisa
Kawamura,
H.
Kenmotsu,
T.
Taira,
S.
Omori,
K.
Nakashima,
K.
Wakuda,
A.
Ono,
T.
Naito,
H.
Murakami,
K.
Mori,
T.
Nakajima,
Y.
Ohde,
M.
Endo,
Toshiaki
Takahashi
(2016)
Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
Cancer Science, 107
-
J.
Han,
Dong-Wan
Kim,
J.
Koh,
B.
Keam,
T.
Kim,
Y.
Jeon,
Se-Hoon
Lee,
D.
Chung,
D.
Heo
(2016)
Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.
Clinical lung cancer, 17 4
-
K.
Shien,
S.
Toyooka,
H.
Yamamoto,
J.
Soh,
M.
Jida,
K.
Thu,
Shinsuke
Hashida,
Y.
Maki,
E.
Ichihara,
Hiroaki
Asano,
K.
Tsukuda,
N.
Takigawa,
K.
Kiura,
A.
Gazdar,
W.
Lam,
S.
Miyoshi
(2013)
Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.
Cancer research, 73 10
-
J.
Zugazagoitia,
A.
Gómez-Rueda,
E.
Jantus-Lewintre,
D.
Isla,
C.
Camps,
Inmaculada
Ramos,
J.
Trigo,
R.
Bernabé,
O.
Juan-Vidal,
J.
Sanchez-Torres,
R.
García-Campelo,
M.
Provencio,
E.
Felip,
J.
Castro,
I.
Faull,
R.
Lanman,
S.
Ponce-Aix,
L.
Paz-Ares,
P.
Garrido
(2019)
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Lung cancer, 134
-
Esra
Akbay,
Esra
Akbay,
S.
Koyama,
J.
Carretero,
Abigail
Altabef,
Abigail
Altabef,
J.
Tchaicha,
J.
Tchaicha,
Camilla
Christensen,
Camilla
Christensen,
Oliver
Mikse,
Oliver
Mikse,
A.
Cherniack,
Ellen
Beauchamp,
Trevor
Pugh,
M.
Wilkerson,
P.
Fecci,
M.
Butaney,
J.
Reibel,
J.
Reibel,
Margaret
Soucheray,
Travis
Cohoon,
Travis
Cohoon,
P.
Jänne,
M.
Meyerson,
M.
Meyerson,
D.
Hayes,
Geoffrey
Shapiro,
T.
Shimamura,
L.
Sholl,
S.
Rodig,
G.
Freeman,
P.
Hammerman,
G.
Dranoff,
Kwok-kin
Wong
(2013)
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Cancer discovery, 3 12
-
J.
Park,
M.
Hong,
Y.
Chun,
H.
Kim,
B.
Cho
(2019)
A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs.
Lung cancer, 134
-
L.
Gandhi,
D.
Rodríguez-Abreu,
S.
Gadgeel,
E.
Esteban,
E.
Felip,
F.
Angelis,
M.
Dómine,
P.
Clingan,
M.
Hochmair,
S.
Powell,
S.
Cheng,
H.
Bischoff,
N.
Peled,
F.
Grossi,
R.
Jennens,
M.
Reck,
R.
Hui,
E.
Garon,
M.
Boyer,
B.
Rubio-Viqueira,
S.
Novello,
T.
Kurata,
J.
Gray,
J.
Vida,
Ziwen
Wei,
Jing
Yang,
H.
Raftopoulos,
C.
Pietanza,
M.
Garassino
(2018)
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
The New England Journal of Medicine, 378
-
P.
Gregory,
A.
Bert,
Emily
Paterson,
S.
Barry,
A.
Tsykin,
G.
Farshid,
M.
Vadas,
Y.
Khew-Goodall,
G.
Goodall
(2008)
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
Nature Cell Biology, 10
-
J.
Thiery,
J.
Thiery,
H.
Acloque,
R.
Huang,
R.
Huang,
M.
Nieto
(2009)
Epithelial-Mesenchymal Transitions in Development and Disease
Cell, 139
-
K.
Yonesaka,
N.
Takegawa,
Satomi
Watanabe,
K.
Haratani,
H.
Kawakami,
K.
Sakai,
Y.
Chiba,
N.
Maeda,
T.
Kagari,
K.
Hirotani,
K.
Nishio,
K.
Nakagawa
(2018)
An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC
Oncogene, 38
-
Y.
Wu,
D.
Planchard,
S.
Lu,
H.
Sun,
N.
Yamamoto,
D-W.
Kim,
D.
Tan,
J.
Yang,
M.
Azrif,
T.
Mitsudomi,
K.
Park,
R.
Soo,
J.
Chang,
A.
Alip,
S.
Peters,
J.
Douillard
(2019)
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Annals of Oncology, 30
-
C.
Corte,
U.
Malapelle,
E.
Vigliar,
F.
Pepe,
G.
Troncone,
V.
Ciaramella,
T.
Troiani,
E.
Martinelli,
V.
Belli,
F.
Ciardiello,
F.
Morgillo
(2017)
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
Oncotarget, 8
-
TATTON Phase Ib expansion cohort: osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)